

Supplemental Table 1 – Baseline Demographics, Disease and Prior Treatment

	Overall		Cohort			
			iNKT		iNKT/GM-CSF	
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%
Sex						
Male	7	77.8	2	66.7	5	83.3
Female	2	22.2	1	33.3	1	16.7
Race						
White	9	100.0	3	100.0	6	100.0
Ethnicity						
Non-Hispanic	8	88.9	3	100.0	5	83.3
Not known	1	11.1	-	-	1	16.7
Initial stage						
IIB	1	11.1	-	-	1	16.7
IIIA	1	11.1	1	33.3	-	-
IIIC	2	22.2	1	33.3	1	16.7
IV	5	55.6	1	33.3	4	66.7
ECOG PS						
0	8	88.9	3	100.0	5	83.3
1	1	11.1	-	-	1	16.7
Histology						
Superficial spreading melanoma	2	22.2	2	66.7	-	-
Nodular melanoma	5	55.6	1	33.3	4	66.7
Lentigo maligna melanoma	1	11.1	-	-	1	16.7
Ocular melanoma	1	11.1	-	-	1	16.7
Site of tumor						
Abdomen	1	11.1	1	33.3	-	-
Back	1	11.1	-	-	1	16.7
Eyes	1	11.1	-	-	1	16.7
Lymph nodes axillary	1	11.1	-	-	1	16.7
Right Arm	1	11.1	-	-	1	16.7
Skin	3	33.3	1	33.3	2	33.3
Skull/Face	1	11.1	1	33.3	-	-
Had prior recurrence?						
Yes	9	100.0	3	100.0	6	100.0
Lymph node dissection						
No	2	22.2	-	-	2	33.3
Yes	7	77.8	3	100.0	4	66.7
LN dissection positive?						
N/A or not done	2	22.2	-	-	2	33.3
No	4	44.4	1	33.3	3	50.0
Yes	3	33.3	2	66.7	1	16.7

	<i>N</i>	<i>Mean</i>	<i>S.D.</i>	<i>Min</i>	<i>Median</i>	<i>Max</i>
Age (yrs)	9	61	11	49	54	76
Months since initial presentation	8	37	35	3	29	117
Number prior recurrences	9	1	0.4	1	1	2

Subject	Pre- Expansion % iNKT	Post- Expansion % iNKT	% CD4+ iNKT	Total iNKT	iNKT / Infusion
001	54	54	74	5.88E+8	1.35E+08
002	73	66	5	2.24E+8	7.19E+07
003	19	28	72	1.13E+07	3.60E+06
004	70	72	47	5.83E+07	2.49E+07
005	47	66	70	2.46E+8	1.53E+08
006	31	74	50	9.89E+8	1.85E+08
007	4	13	72	1.36E+8	2.73E+07
008	21	87	21	1.26E+9	2.17E+08
009	62	30	77	2.70E+8	7.28E+07

Supplemental Table 2. Summary of iNKT recovery & purity pre- & post-expansion

The iNKT cell product was characterized as described in M&M.

Subject	%IFNγ+ CD4- iNKT	IFNγ+ CD4- iNKT MFI	% IFNγ+ CD4+ iNKT	IFNγ+ CD4+ iNKT MFI	%IL- 4+ iNKT (MFI)	%IL- 10+ iNKT (MFI)
001	52	10	43	6	NT	ND
002	52	10	NA	NA	ND	ND
003	60	3	70	10	15 (1.2)	NT
004	21	3.5	22	20	NT	ND
005	68	3.3	61	3.3	ND	ND
006	18	2.4	13	2.6	10 (2.6)	7 (2.5)
007	11	2.0	24	0.7	17 (0.8)	ND
008	NT	NT	NT	NT	NT	NT
009	55	1.5	30	2.5	NT	NT

Supplemental Table 3. Functional activity of the iNKT product

Functional activity of the iNKT product was characterized as described in M&M. NA: not applicable (no significant CD4⁺ population); ND: not detectable; NT, not tested.

Toxicities – The worst grade of a reported toxicity is summarized for each patient. The following tables contain only those toxicities that were considered to be at least “possibly” related to therapy. All 9 patients reported toxicities that were related to treatment, all of grade 1 or 2. A complete listing of all toxicities, regardless of relatedness, is presented in the Appendix.

Supplemental Table 4a – Grade-2 Toxicities at Least Possibly Related to Treatment

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
6	iNKT/GM-CSF	Infusion 2	METABOLIC/LABORATORY	Hypophosphatemia	Possibly	Both
7	iNKT/GM-CSF	Infusion 1	CONSTITUTIONAL SYMPTOMS	Fatigue	Possibly	Both
8	iNKT/GM-CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Fatigue	Possibly	Both
		Infusion 2	CONSTITUTIONAL SYMPTOMS	Constitutional- other	Possibly	Both
		Infusion 2	DERMATOLOGY/SKIN	Injection site reaction	Possibly	Both
9	iNKT/GM-CSF	Infusion 2	DERMATOLOGY/SKIN	Pruritus/itching	Possibly	Both

Supplemental Table 4b – Grade-1 Toxicities at Least Possibly Related to Treatment

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
1	iNKT	Infusion 1	CONSTITUTIONAL SYMPTOMS	Constitutional- other	Possibly	iNKT Cells
		Infusion 3	PAIN	Back- pain	Possibly	iNKT Cells
2	iNKT	Infusion 1	CONSTITUTIONAL SYMPTOMS	Odor (patient odor)	Definitely	
		Infusion 1	CONSTITUTIONAL SYMPTOMS	Constitutional- other	Possibly	iNKT Cells
		Infusion 1	DERMATOLOGY/SKIN	Pruritus/itching	Probably	
		Infusion 1	PAIN	Head/headache	Possibly	iNKT Cells
		Infusion 3	PAIN	Joint- pain	Possibly	iNKT Cells
		Infusion 3	PAIN	Muscle- pain	Possibly	iNKT Cells
		Infusion 3	PAIN	Throat/pharynx/larynx- pain	Possibly	iNKT Cells
3	iNKT/GM-CSF	Infusion 1	CARDIOVASUCLAR (GENERAL)	Hypertension	Possibly	Both
		Infusion 1	DERMATOLOGY/SKIN	Pruritus/itching	Possibly	Both
		Infusion 2	BLOOD/BONE MARROW	Leukocytes	Probably	
		Infusion 2	DERMATOLOGY/SKIN	Injection site reaction	Definitely	
4	iNKT	Infusion 1	CARDIOVASUCLAR (GENERAL)	Hypotension	Possibly	iNKT Cells
		Infusion 1	PAIN	Head/headache	Possibly	iNKT Cells

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
		Infusion 2	CONSTITUTIONAL SYMPTOMS	Odor (patient odor)	Definitely	
		Infusion 2	ENDOCRINE	Hot flashes	Possibly	iNKT Cells
		Infusion 3	NEUROLOGY	Neurologic-other	Possibly	iNKT Cells
5	iNKT/GM- CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Rigors/chills	Possibly	Both
		Infusion 2	DERMATOLOGY/SKIN	Pruritus/itching	Possibly	Both
		Infusion 2	DERMATOLOGY/SKIN	Rash/desquamation	Possibly	Both
		Infusion 2	PAIN	Joint- pain	Possibly	Both
		Infusion 2	PAIN	Muscle- pain	Possibly	Both
		Infusion 3	DERMATOLOGY/SKIN	Injection site reaction	Probably	
6	iNKT/GM- CSF	Infusion 1	GASTROINTESTINAL	Constipation	Possibly	iNKT Cells
		Infusion 2	CONSTITUTIONAL SYMPTOMS	Rigors/chills	Possibly	Both
		Infusion 2	GASTROINTESTINAL	Nausea	Possibly	Both
		Infusion 2	METABOLIC/LABORATO RY	Hyperglycemia	Possibly	Both
		Infusion 2	METABOLIC/LABORATO RY	Hypomagnesemia	Possibly	Both
		Infusion 2	PAIN	Muscle- pain	Possibly	Both
		Infusion 3	GASTROINTESTINAL	Anorexia	Possibly	Both
		Infusion 3	PAIN	Back- pain	Possibly	Both
		Infusion 3	PAIN	Joint- pain	Possibly	Both
		Infusion 3	PULMONARY/UPPER RESPIRATORY	Dyspnea	Possibly	Both
7	iNKT/GM- CSF	Follow-Up 1	PULMONARY/UPPER RESPIRATORY	Cough	Possibly	Both
		Infusion 1	DERMATOLOGY/SKIN	Injection site reaction	Probably	
		Infusion 1	PAIN	Back- pain	Possibly	Both
		Infusion 1	PAIN	Muscle- pain	Possibly	GM-CSF
		Infusion 3	CONSTITUTIONAL SYMPTOMS	Fever w/o neutropenia	Possibly	Both
		Infusion 3	DERMATOLOGY/SKIN	Pruritus/itching	Probably	
		Infusion 3	PAIN	Throat/pharynx/larynx- pain	Possibly	Both
8	iNKT/GM- CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Rigors/chills	Possibly	Both
		Infusion 2	GASTROINTESTINAL	Nausea	Possibly	Both
		Infusion 2	PAIN	Head/headache	Possibly	Both
		Infusion 3	DERMATOLOGY/SKIN	Pruritus/itching	Definitely	
		Infusion 3	PAIN	Throat/pharynx/larynx- pain	Possibly	Both
		Infusion 3	PAIN	Pain-other	Definitely	
9	iNKT/GM- CSF	Infusion 2	BLOOD/BONE MARROW	Neutrophils	Possibly	iNKT Cells
		Infusion 2	CONSTITUTIONAL SYMPTOMS	Fatigue	Possibly	Both

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
		Infusion 2	CONSTITUTIONAL SYMPTOMS	Odor (patient odor)	Definitely	
		Infusion 2	DERMATOLOGY/SKIN	Injection site reaction	Definitely	
		Infusion 2	PAIN	Joint- pain	Possibly	Both
		Infusion 2	PAIN	Stomach- pain	Possibly	Both
		Infusion 3	PAIN	Muscle- pain	Possibly	GM-CSF
		Infusion 3	PULMONARY/UPPER RESPIRATORY	Nasal cavity/paranasal sinus reaction	Possibly	Both

Supplemental Table 5 – Number of Patients with Related Toxicities According to Category

		Toxicity Grade CTCAE v3.0	
		1	2
Toxicity Category CTCAE v3.0	Toxicity Description CTCAE v3.0		
BLOOD/BONE MARROW	Leukocytes	1	-
	Neutrophils	1	-
CARDIOVASUCLAR (GENERAL)	Hypertension	1	-
	Hypotension	1	-
CONSTITUTIONAL SYMPTOMS	Constitutional- other	2	1
	Fatigue	1	2
	Fever w/o neutropenia	1	-
	Odor (patient odor)	3	-
	Rigors/chills	3	-
DERMATOLOGY/SKIN	Injection site reaction	4	1
	Pruritus/itching	5	1
	Rash/desquamation	1	-
ENDOCRINE	Hot flashes	1	-
GASTROINTESTINAL	Anorexia	1	-
	Constipation	1	-
	Nausea	2	-
METABOLIC/LABORATORY	Hyperglycemia	1	-
	Hypomagnesemia	1	-
	Hypophosphatemia	-	1
NEUROLOGY	Neurologic-other	1	-
PAIN	Back- pain	3	-
	Head/headache	3	-
	Joint- pain	4	-
	Muscle- pain	5	-
	Pain-other	1	-
	Stomach- pain	1	-
	Throat/pharynx/larynx- pain	3	-
PULMONARY/UPPER RESPIRATORY	Cough	1	-
	Dyspnea	1	-
	Nasal cavity/paranasal sinus reaction	1	-

Supplemental Table 6 – DTH Skin Test

<i>CASE NUMBER</i>	<i>Timepoint</i>	<i>Was DTH Given?</i>	<i>Location of Injection</i>	<i>Reaction at Injection Site?</i>	<i>Erythema?</i>	<i>Erythema area (cm**2)</i>	<i>Induration?</i>	<i>Induration area (cm**2)</i>	<i>Itching?</i>
1	Baseline	Yes	Right arm	Yes	Yes	16.00	No	.	No
1	PI 3, Visit 2	Yes	Right arm	Yes	No	.	Yes	16.00	No
2	Baseline	Yes	Right arm	No	No	.	No	.	No
2	PI 3, Visit 2	Yes	Right arm	No	No	.	No	.	No
3	Baseline	Yes	Right arm	Yes	No	.	Yes	4.41	No
3	PI 3, Visit 2	Yes	Right arm	Yes	Yes	16.00	No	.	No
4	Baseline	Yes	Left arm	Yes	No	.	Yes	1.44	No
4	PI 3, Visit 2	Yes	Left arm	Yes	No	.	Yes	2.25	No
5	Baseline	Yes	Left arm	Yes	Yes	8.40	Yes	8.40	No
5	PI 3, Visit 2	No	.	N/A	N/A	.	N/A	.	N/A
6	Baseline	Yes	Right arm	Yes	No	.	Yes†	N/A.	No
6	PI 3, Visit 2	Yes	Right arm	Yes	Yes	1.50	Yes	1.50	No
7	Baseline	Yes	Right arm	Yes	Yes	4.41	Yes	4.41	No
7	PI 3, Visit 2	Yes	Left arm	Yes	Yes	133.10	Yes	3.78	No
8	Baseline	Yes	Right arm	Yes	Yes	7.02	Yes	3.12	No
8	PI 3, Visit 2	Yes	Left arm	Yes	Yes	4.00	Yes	60.00	Yes
9	Baseline	Yes	Right arm	No	No	.	No	.	No
9	PI 3, Visit 2	Yes	Right arm	No	No	.	No	.	No

† Length = 1.5 cm, width missing.

Time on Study, Progression and Survival – Outcome data were updated on April 3, 2015.
Median follow-up for this patient cohort is 63 months (95% CI 53 to 85 months). As of 4/3/15, three patients had died, and six had disease progression. All patients who died also had disease progression.

Supplemental Table 7 – Time on Treatment, Time on Study

		<i>N</i>	<i>Mean</i>	<i>S.D.</i>	<i>Min</i>	<i>Median</i>	<i>Max</i>
<i>Weeks on Tx</i>	<i>Overall</i>	9	16.8	6.5	13.1	14.3	33.0
	<i>Cohort</i>				14.9		
	<i>iNKT</i>	3	16.9	2.8		15.7	20.0
	<i>iNKT/GM-CSF</i>	6	16.7	8.0	13.1	13.4	33.0
<i>Weeks on Study</i>	<i>Overall</i>	9	48.5	32.4	15.3	42.3	127.0
	<i>Cohort</i>			47.3	44.7		
	<i>iNKT</i>	3	72.4	3	7	45.6	127.0
	<i>iNKT/GM-CSF</i>	6	36.5	16.3	15.3	40.6	59.9

Supplemental Table 8 – Response and Survival

			<i>Cohort</i>			
			<i>iNKT</i>		<i>iNKT/GM-CSF</i>	
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
BOR		33.		66.		
<i>PD</i>	3	3	2	7	1	16.7
<i>SD</i>	6	66.7	1	33.3	5	83.3
Progression?		33.		33.		
<i>No</i>	3	3	1	3	2	33.3
<i>Yes</i>	6	66.7	2	66.7	4	66.7
Vital Status		66.		66.		
<i>Alive</i>	6	7	2	7	4	66.7
<i>Died</i>	3	33.3	1	33.3	2	33.3

Supplemental Appendix

Table SA1 – Grade-5 Toxicities (all relatedness)

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
5	iNKT/GM-CSF	Infusion 3	DEATH	Death - disease progression NOS	Not related	

Table SA2 – Grade- 4 Toxicities (all relatedness)

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
5	iNKT/GM-CSF	Infusion 3	HEPATOBIILIARY/PANCREA S	Liver dysfunction/failure	Not related	
		Infusion 3	RENAL/GENITOURINARY	Renal failure	Not related	

Table SA3 – Grade-3 Toxicities (all relatedness)

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
5	iNKT/GM-CSF	Infusion 3	PAIN	Back- pain	Unlikely	
		Infusion 3	PAIN	Bone- pain	Unlikely	
8	iNKT/GM-CSF	Follow-Up 1	METABOLIC/LABORATORY	Hyponatremia	Unlikely	

Table SA4 – Grade-2 Toxicities (all relatedness)

<i>CASE NUMBER</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
2	iNKT	Follow-Up 1	INFECTION	Infection w/ unk ANC skin (cellulitis)	Unlikely	
5	iNKT/GM-CSF	Infusion 3	GASTROINTESTINAL	Distention/bloating- abdominal	Unlikely	
5	iNKT/GM-CSF	Infusion 3	METABOLIC/LABORATORY	Alkaline phosphatase	Not related	
5	iNKT/GM-CSF	Infusion 3	METABOLIC/LABORATORY	ALT- SGPT	Not related	
5	iNKT/GM-CSF	Infusion 3	METABOLIC/LABORATORY	AST- SGOT	Not related	
5	iNKT/GM-CSF	Infusion 3	METABOLIC/LABORATORY	Hyperkalemia	Not related	
5	iNKT/GM-CSF	Infusion 3	PULMONARY/UPPER RESPIRATORY	Atelectasis	Not related	
6	iNKT/GM-CSF	Infusion 2	METABOLIC/LABORATORY	Hypophosphatemia	Possibly	Both
7	iNKT/GM-CSF	Infusion 1	CONSTITUTIONAL SYMPTOMS	Fatigue	Possibly	Both
8	iNKT/GM-CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Fatigue	Possibly	Both

<i>CASE NUMBE R</i>	<i>Cohort</i>	<i>VISIT</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
8	iNKT/GM- CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Constitutional- other	Possibly	Both
8	iNKT/GM- CSF	Infusion 2	DERMATOLOGY/SKIN	Injection site reaction	Possibly	Both
9	iNKT/GM- CSF	Infusion 2	DERMATOLOGY/SKIN	Pruritus/itching	Possibly	Both
9	iNKT/GM- CSF	Infusion 2	METABOLIC/LABORATORY	Hyperglycemia	Not related	

Table SA5 – Grade-1 Toxicities (all relatedness)

<i>CASE VUMBER</i>	<i>Cohort</i>	<i>VISIT REFNAME</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
1	iNKT	Follow-Up 1	DERMATOLOGY/SKIN	Rash/desquamation	Unlikely	
1	iNKT	Follow-Up 1	LYMPHATICS	Edema limb	Not related	
1	iNKT	Follow-Up 1	PAIN	Dental/teeth/peridontal- pain	Not related	
1	iNKT	Follow-Up 2	PAIN	Muscle- pain	Not related	
1	iNKT	Infusion 1	CONSTITUTIONAL SYMPTOMS	Constitutional- other	Possibly	iNKT Cells
1	iNKT	Infusion 3	PAIN	Back- pain	Possibly	iNKT Cells
2	iNKT	Follow-Up 1	CONSTITUTIONAL SYMPTOMS	Fatigue	Unlikely	
2	iNKT	Follow-Up 1	GASTROINTESTINAL	Diarrhea w/o prior colostomy	Unlikely	
2	iNKT	Follow-Up 1	GASTROINTESTINAL	Nausea	Unlikely	
2	iNKT	Follow-Up 1	MUSCULOSKELETAL/SOFT TISSUE	Musculoskeletal/soft tissue-other	Unlikely	
2	iNKT	Follow-Up 1	SYNDROMES	Syndromes-other	Unlikely	
2	iNKT	Infusion 1	CONSTITUTIONAL SYMPTOMS	Odor (patient odor)	Definitely	
2	iNKT	Infusion 1	CONSTITUTIONAL SYMPTOMS	Constitutional- other	Possibly	iNKT Cells
2	iNKT	Infusion 1	DERMATOLOGY/SKIN	Pruritus/itching	Probably	
2	iNKT	Infusion 1	PAIN	Head/headache	Possibly	iNKT Cells
2	iNKT	Infusion 3	PAIN	Joint- pain	Possibly	iNKT Cells
2	iNKT	Infusion 3	PAIN	Muscle- pain	Possibly	iNKT Cells
2	iNKT	Infusion 3	PAIN	Throat/pharynx/larynx- pain	Possibly	iNKT Cells
3	iNKT/GM- CSF	Infusion 1	CARDIOVASUCLAR (GENERAL)	Hypertension	Possibly	Both
3	iNKT/GM- CSF	Infusion 1	DERMATOLOGY/SKIN	Pruritus/itching	Possibly	Both
3	iNKT/GM- CSF	Infusion 2	BLOOD/BONE MARROW	Leukocytes	Probably	
3	iNKT/GM- CSF	Infusion 2	DERMATOLOGY/SKIN	Injection site reaction	Definitely	
4	iNKT	Follow-Up 1	NEUROLOGY	Neuropathy-sensory	Unlikely	
4	iNKT	Infusion 1	CARDIOVASUCLAR (GENERAL)	Hypotension	Possibly	iNKT Cells
4	iNKT	Infusion 1	PAIN	Head/headache	Possibly	iNKT Cells
4	iNKT	Infusion 2	CONSTITUTIONAL SYMPTOMS	Odor (patient odor)	Definitely	
4	iNKT	Infusion 2	ENDOCRINE	Hot flashes	Possibly	iNKT Cells

<i>CASE VUMBER</i>	<i>Cohort</i>	<i>VISIT REFNAME</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
4	iNKT	Infusion 3	NEUROLOGY	Neurologic-other	Possibly	iNKT Cells
5	iNKT/GM- CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Rigors/chills	Possibly	Both
5	iNKT/GM- CSF	Infusion 2	DERMATOLOGY/SKIN	Pruritus/itching	Possibly	Both
5	iNKT/GM- CSF	Infusion 2	DERMATOLOGY/SKIN	Rash/desquamation	Possibly	Both
5	iNKT/GM- CSF	Infusion 2	GASTROINTESTINAL	Flatulence	Unlikely	
5	iNKT/GM- CSF	Infusion 2	PAIN	Joint- pain	Possibly	Both
5	iNKT/GM- CSF	Infusion 2	PAIN	Muscle- pain	Possibly	Both
5	iNKT/GM- CSF	Infusion 3	BLOOD/BONE MARROW	Hemoglobin	Unlikely	
5	iNKT/GM- CSF	Infusion 3	CARDIOVASCULAR (ARRHYTHMIA)	Arrhythmia-other	Not related	
5	iNKT/GM- CSF	Infusion 3	COAGULATION	INR	Not related	
5	iNKT/GM- CSF	Infusion 3	COAGULATION	PTT	Not related	
5	iNKT/GM- CSF	Infusion 3	DERMATOLOGY/SKIN	Injection site reaction	Probably	
5	iNKT/GM- CSF	Infusion 3	METABOLIC/LABORATORY	Bilirubin	Not related	
5	iNKT/GM- CSF	Infusion 3	METABOLIC/LABORATORY	Hypocalcemia	Unlikely	
5	iNKT/GM- CSF	Infusion 3	METABOLIC/LABORATORY	Proteinuria	Unlikely	
5	iNKT/GM- CSF	Infusion 3	METABOLIC/LABORATORY	Hyponatremia	Unlikely	
5	iNKT/GM- CSF	Infusion 3	PULMONARY/UPPER RESPIRATORY	Cough	Unlikely	
6	iNKT/GM- CSF	Follow-Up 1	CONSTITUTIONAL SYMPTOMS	Fatigue	Unlikely	
6	iNKT/GM- CSF	Follow-Up 1	DERMATOLOGY/SKIN	Induration/fibrosis	Unlikely	
6	iNKT/GM- CSF	Infusion 1	GASTROINTESTINAL	Constipation	Possibly	iNKT Cells
6	iNKT/GM- CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Rigors/chills	Possibly	Both
6	iNKT/GM- CSF	Infusion 2	GASTROINTESTINAL	Nausea	Possibly	Both
6	iNKT/GM- CSF	Infusion 2	METABOLIC/LABORATORY	Hyperglycemia	Possibly	Both
6	iNKT/GM- CSF	Infusion 2	METABOLIC/LABORATORY	Hypomagnesemia	Possibly	Both
6	iNKT/GM- CSF	Infusion 2	PAIN	Muscle- pain	Possibly	Both
6	iNKT/GM- CSF	Infusion 3	GASTROINTESTINAL	Anorexia	Possibly	Both

<i>CASE VUMBER</i>	<i>Cohort</i>	<i>VISIT REFNAME</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
6	iNKT/GM-CSF	Infusion 3	PAIN	Back- pain	Possibly	Both
6	iNKT/GM-CSF	Infusion 3	PAIN	Joint- pain	Possibly	Both
6	iNKT/GM-CSF	Infusion 3	PULMONARY/UPPER RESPIRATORY	Dyspnea	Possibly	Both
7	iNKT/GM-CSF	Follow-Up 1	PULMONARY/UPPER RESPIRATORY	Cough	Possibly	Both
7	iNKT/GM-CSF	Infusion 1	ALLERGY/IMMUNOLOGY	Allergy-other	Unlikely	
7	iNKT/GM-CSF	Infusion 1	DERMATOLOGY/SKIN	Injection site reaction	Probably	
7	iNKT/GM-CSF	Infusion 1	PAIN	Back- pain	Possibly	Both
7	iNKT/GM-CSF	Infusion 1	PAIN	Muscle- pain	Possibly	GM-CSF
7	iNKT/GM-CSF	Infusion 3	CONSTITUTIONAL SYMPTOMS	Fever w/o neutropenia	Possibly	Both
7	iNKT/GM-CSF	Infusion 3	DERMATOLOGY/SKIN	Pruritus/itching	Probably	
7	iNKT/GM-CSF	Infusion 3	GASTROINTESTINAL	Anorexia	Unlikely	
7	iNKT/GM-CSF	Infusion 3	PAIN	Throat/pharynx/larynx- pain	Possibly	Both
8	iNKT/GM-CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Rigors/chills	Possibly	Both
8	iNKT/GM-CSF	Infusion 2	GASTROINTESTINAL	Nausea	Possibly	Both
8	iNKT/GM-CSF	Infusion 2	PAIN	Head/headache	Possibly	Both
8	iNKT/GM-CSF	Infusion 3	DERMATOLOGY/SKIN	Pruritus/itching	Definitely	
8	iNKT/GM-CSF	Infusion 3	PAIN	Throat/pharynx/larynx- pain	Possibly	Both
8	iNKT/GM-CSF	Infusion 3	PAIN	Pain-other	Definitely	
9	iNKT/GM-CSF	Follow-Up 2	NEUROLOGY	Dizziness	Unlikely	
9	iNKT/GM-CSF	Infusion 1	BLOOD/BONE MARROW	Leukocytes	Not related	
9	iNKT/GM-CSF	Infusion 2	BLOOD/BONE MARROW	Neutrophils	Possibly	iNKT Cells
9	iNKT/GM-CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Fatigue	Possibly	Both
9	iNKT/GM-CSF	Infusion 2	CONSTITUTIONAL SYMPTOMS	Odor (patient odor)	Definitely	
9	iNKT/GM-CSF	Infusion 2	DERMATOLOGY/SKIN	Injection site reaction	Definitely	
9	iNKT/GM-CSF	Infusion 2	PAIN	Joint- pain	Possibly	Both
9	iNKT/GM-CSF	Infusion 2	PAIN	Stomach- pain	Possibly	Both

<i>CASE VUMBER</i>	<i>Cohort</i>	<i>VISIT REFNAME</i>	<i>Toxicity Category CTCAE v3.0</i>	<i>Toxicity Description CTCAE v3.0</i>	<i>Attribution</i>	<i>Attribution ~ Possible</i>
9	iNKT/GM-CSF	Infusion 3	PAIN	Muscle- pain	Possibly	GM-CSF
9	iNKT/GM-CSF	Infusion 3	PULMONARY/UPPER RESPIRATORY	Nasal cavity/paranasal sinus reaction	Possibly	Both